ALK and neoplasm: As previously stated, ALKi activity is affected by several factors, including tumour intrinsic characteristics (e.g., ALK fusion gene variants or presence of other primary gene co-mutations) and extrinsic factors (e.g., impact of prior treatments such as presence of ALK secondary mutations, or development of by-pass resistances), and also drug-dependent characteristics (e.g., blood-brain barrier crossing).